Celsion Looking To Break Liver Cancer (CLSN)
Celsion Corp. (NASDAQ: CLSN) has announced that its global Phase III Primary Liver Cancer trial is proceeding as planned. After receipt of FDA agreement in January of 2008 for its pivotal Phase III Primary Liver Cancer trial in the United States, Celsion says that it has obtained regulatory approval to conduct its Phase III safety and efficacy study of ThermoDox® in Hong Kong, Taiwan, Korea, Canada, and Italy. It also anticipates that a clinical trial agreement will be obtained in China before the end of 2008.
Celsion also noted that site initiation and patient enrollment are tracking well against its most recent projections.
Celsion also reported that Yakult Honsha is proceeding with plans to initiate a clinical program in Japan to study ThermoDox® for the treatment of primary liver cancer. As previously announced, Yakult will begin pre-clinical and clinical studies of ThermoDox® to support requirements for drug registration in Japan.
This stock made a major downside mystery move yesterday. It also doesn’t take much to move the stock as it only traded 46,000 shares yesterday. Some of the prioce moves may be exaggerated or stretched as well because of its wide bid-ask spread.
If the stock market continues in the same sort of swings it has been lately, they may have many more self-medicating via booze client down the road.
Jon C. Ogg
September 24, 2008